Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.

The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognosti...

Full description

Bibliographic Details
Main Authors: Julia Thierauf, Stephanie E Weissinger, Johannes A Veit, Annette Affolter, Natalia K Laureano, Dirk Beutner, Gregor Heiduschka, Lorenz Kadletz, Moritz Meyer, Alexander Quaas, Peter Plinkert, Thomas K Hoffmann, Jochen Hess
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5875788?pdf=render
id doaj-53d2a5a113ff46f899b36f69de9d82eb
record_format Article
spelling doaj-53d2a5a113ff46f899b36f69de9d82eb2020-11-25T02:48:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019498910.1371/journal.pone.0194989Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.Julia ThieraufStephanie E WeissingerJohannes A VeitAnnette AffolterNatalia K LaureanoDirk BeutnerGregor HeiduschkaLorenz KadletzMoritz MeyerAlexander QuaasPeter PlinkertThomas K HoffmannJochen HessThe transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated.SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival.High SOX2 expression was found in 14 (31%) primary tumor specimens and was significantly correlated with a N0 lymph node status (p = 0.04), while low SOX2 expression was correlated with a solid growth pattern (p = 0.031). Of the 45 patients, 27 tumor samples resembled an EMT-like phenotype, as assessed by high vimentin and low E-cadherin levels. However, in HNACC SOX2 levels were neither correlated with vimentin nor with E-cadherin expression, further supporting a context dependent regulation and function of SOX2 in distinct tumor entities.The absence of SOX2 was predominantly found in solid HNACC, which are characterized by a more aggressive phenotype in ACC. However, the underlying molecular mechanisms of SOX2 regulation and function in distinct HNACC subgroups remain to be fully elucidated.http://europepmc.org/articles/PMC5875788?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Julia Thierauf
Stephanie E Weissinger
Johannes A Veit
Annette Affolter
Natalia K Laureano
Dirk Beutner
Gregor Heiduschka
Lorenz Kadletz
Moritz Meyer
Alexander Quaas
Peter Plinkert
Thomas K Hoffmann
Jochen Hess
spellingShingle Julia Thierauf
Stephanie E Weissinger
Johannes A Veit
Annette Affolter
Natalia K Laureano
Dirk Beutner
Gregor Heiduschka
Lorenz Kadletz
Moritz Meyer
Alexander Quaas
Peter Plinkert
Thomas K Hoffmann
Jochen Hess
Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
PLoS ONE
author_facet Julia Thierauf
Stephanie E Weissinger
Johannes A Veit
Annette Affolter
Natalia K Laureano
Dirk Beutner
Gregor Heiduschka
Lorenz Kadletz
Moritz Meyer
Alexander Quaas
Peter Plinkert
Thomas K Hoffmann
Jochen Hess
author_sort Julia Thierauf
title Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
title_short Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
title_full Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
title_fullStr Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
title_full_unstemmed Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
title_sort low sox2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description The transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated.SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival.High SOX2 expression was found in 14 (31%) primary tumor specimens and was significantly correlated with a N0 lymph node status (p = 0.04), while low SOX2 expression was correlated with a solid growth pattern (p = 0.031). Of the 45 patients, 27 tumor samples resembled an EMT-like phenotype, as assessed by high vimentin and low E-cadherin levels. However, in HNACC SOX2 levels were neither correlated with vimentin nor with E-cadherin expression, further supporting a context dependent regulation and function of SOX2 in distinct tumor entities.The absence of SOX2 was predominantly found in solid HNACC, which are characterized by a more aggressive phenotype in ACC. However, the underlying molecular mechanisms of SOX2 regulation and function in distinct HNACC subgroups remain to be fully elucidated.
url http://europepmc.org/articles/PMC5875788?pdf=render
work_keys_str_mv AT juliathierauf lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT stephanieeweissinger lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT johannesaveit lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT annetteaffolter lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT nataliaklaureano lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT dirkbeutner lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT gregorheiduschka lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT lorenzkadletz lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT moritzmeyer lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT alexanderquaas lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT peterplinkert lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT thomaskhoffmann lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
AT jochenhess lowsox2expressionmarksadistinctsubsetofadenoidcysticcarcinomaoftheheadandneckandisassociatedwithanadvancedtumorstage
_version_ 1724748098482208768